Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Nammi Therapeutics Inc. has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 7 examiners across 6 art units, showing broad distribution with some technical-unit overlap.
CABRAL, ROBERT S is the busiest examiner, with 1 pending matter. Counsel should use centralized docket oversight while preparing individualized responses and comparing recurring biotechnology or pharmaceutical issues across the art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (14%) |
| §112 only | 2 (29%) |
| Double-patenting + other | 3 (43%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CABRAL, ROBERT S | 1 | 62.8% | +32.3% |
| DAVIS, BRIAN J | 1 | 84.8% | -3.9% |
| WEIDNER, ADAM M | 1 | 63.7% | +33.6% |
| WESTERBERG, NISSA M | 1 | 23.4% | +37.3% |
| HOWELL, THEODORE R | 1 | 66.9% | +25.1% |
| STEINKE, SEAN JAMES | 1 | 12.5% | +42.9% |
| DENT, ALANA HARRIS | 1 | 44.1% | +32.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18831041 | Formulated and/or Co-Formulated Nanocarrier Compositions Containing TFGß Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | DAVIS, BRIAN J | 20d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18445604 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll-Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof C | WESTERBERG, NISSA M | 29d |
| 17803774 | Formulated and/or Co-Formulated Liposome Compositions Containing Immunogenic Cell Death (ICD) Inducing Prodrugs Useful In The Treatment of Cancer and Methods Thereof | STEINKE, SEAN JAMES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18445604 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll-Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof C | WESTERBERG, NISSA M | 29d |
| 18751742 | Formulated and/or Co-Formulated Liposome Compositions Containing PD-1 Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | CABRAL, ROBERT S | — |
| 18445651 | Fusion Protein Composition(s) Comprising Masked Type I Interferons (IFNa and IFNb) For Use in the Treatment of Cancer and Methods Thereof | WEIDNER, ADAM M | — |
| 18445036 | Formulated and/or Co-Formulated Lipid Nanocarriers Compositions Containing Toll-Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof | HOWELL, THEODORE R | — |
| 17803774 | Formulated and/or Co-Formulated Liposome Compositions Containing Immunogenic Cell Death (ICD) Inducing Prodrugs Useful In The Treatment of Cancer and Methods Thereof | STEINKE, SEAN JAMES | — |
| 17803392 | Fusion Protein Composition(S) Comprising Masked Type I Interferons (IFNa and IFNß) For Use in the Treatment of Cancer and Methods Thereof | DENT, ALANA HARRIS | — |
| Art Unit | Apps |
|---|---|
| 1614 | 2 |
| 1675 | 1 |
| 1618 | 1 |
| 1628 | 1 |
| 1619 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18751742 | Formulated and/or Co-Formulated Liposome Compositions Containing PD-1 Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | CABRAL, ROBERT S | 1614 | §112 | Non-Final OA | — | Pending | Jun 24, 2024 |
| 18831041 | Formulated and/or Co-Formulated Nanocarrier Compositions Containing TFGß Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | DAVIS, BRIAN J | 1614 | §112 | Final Rejection | 20d | Pending | May 13, 2024 |
| 18445651 | Fusion Protein Composition(s) Comprising Masked Type I Interferons (IFNa and IFNb) For Use in the Treatment of Cancer and Methods Thereof | WEIDNER, ADAM M | 1675 | §102§103DP | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18445604 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll-Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof C | WESTERBERG, NISSA M | 1618 | §103§112DP | Final Rejection | 29d | Pending | Nov 15, 2023 |
| 18445036 | Formulated and/or Co-Formulated Lipid Nanocarriers Compositions Containing Toll-Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof | HOWELL, THEODORE R | 1628 | §103 | Final Rejection | — | Pending | Mar 10, 2023 |
| 17803774 | Formulated and/or Co-Formulated Liposome Compositions Containing Immunogenic Cell Death (ICD) Inducing Prodrugs Useful In The Treatment of Cancer and Methods Thereof | STEINKE, SEAN JAMES | 1619 | §103§112 | Non-Final OA | — | Pending | Nov 17, 2022 |
| 17803392 | Fusion Protein Composition(S) Comprising Masked Type I Interferons (IFNa and IFNß) For Use in the Treatment of Cancer and Methods Thereof | DENT, ALANA HARRIS | 1643 | §102§112DP | Non-Final OA | — | Pending | Jun 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNammi Therapeutics Inc. has 7 pending office actions as of October 2026, spread across 6 art units and 7 examiners.
Robert S Cabral has the most, with 1 of Nammi Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
